Wellness companies eager to avoid WeightWatchers’ fate embrace weight-loss drugs

#Wellness #companies #eager #avoid #WeightWatchers #fate #embrace #weightloss #drugs

New York: Health and fitness companies are accepting weight loss drugs and are offering around them in an attempt to avoid the fate of Weight Vouchers, which announced bankruptcy this week, which increased the widespread use of new blockbuster drugs.

But some of the nearest rivals of the Weight Watch, new tele -health companies, face a new challenge, as the federal regulators eliminate the cheap version of Novo Nordsesk’s Vigo and Eli Lily’s zipbound that has become a major part of companies’ sales. The success of television companies may eventually depend on the partnership of brand drug makers, a analyst said.

Weight Vouchers filed for bankruptcy on Tuesday, when the Americans eliminated the weight management business in favor of copies of Novo and Lily Drugs and Pharmacies, which can reduce the weight of a person by 15-20 %. GLP-1 is known as agonists, from a digestive drug class, which has been eaten by some major companies, including Walmart’s food business.

Weight Vachers, when it filed for bankruptcy, said that the weight management system systemed changing ideas about weight over weight, television companies fully accepting weight loss medicines, and even changing the ideas of changing the fitness impact on tricktok. The company has an agreement with lenders to reorganize its loan and get out of court process.

“Weightwaters, who tried to sell telecommunications and weight loss medicines, contained an old school system that relied on points and collects personally,” said Adam McBride, television company Eden CEO Edin CEO Adam McBride. “I don’t think they are listening to their members,” said McBride.

Eden and rival Nams run a weight -based television platform with a coaching lifestyle.

New companies are selling non -branded versions of weight loss medicines in demand as part of their offerings.

CEO Jeff Cook said clinical subscriptions that provide access to physicians and prescription drugs are higher than half of the nausea.

In rival Hims and Hers, last year, weight loss drugs were 20 % of the drug income, and even the Weight Vouchers relied on such income.

Nam has presented the drug as a kind of superpower weight loss device, which the company has said then leads consumers to other parts of their platform.

“In the last or two months, people who are taking meds are actually logging in more food,” said Nam’s CEO. “They are weighing the maximum and they are engaged in the other aspects of the new program that is better than the flagship program.”

Weight loss medicine bandwagons

Other health companies see the capacity of products and services that benefit from the popularity of new weight loss drugs, which predicts that some analysts will sell $ 150 billion annually in the next decade.

President Moriel Gonzalez said that the health retailer vitamin shop has seen an increase in demand for supplements, which can help reduce appetite, reduce muscle tone and other side effects of GLP-1. A company spokesman said that sales of supplements sold to people who take such medicines have increased by more than 20 % over a year ago.

Last year, the vitamin shop launched a television service, the entire Health RX, which connects consumers to medical providers who can write weight loss medicines and recommend supplements for giving people protein, fiber and multi -vitamins.

Other companies did similar activities. Supplement seller GNC, looking to take advantage of this trend, added a section in stores dedicated to GLP-1 consumers last year, which sold protein powder and fiber.

Weight Vachers themselves are also trying to ache. A spokeswoman said in a statement that GLP-1 medicines for weight loss are a growing and integral part of its business. He said that his program works as a reference to an internal study in which his clinic patients reduced their weight by 21 % of GLP -one drugs and then shifted to their behavior program and lost 2.0 % after 13 weeks.

But easy sales of the cheap version of the drug are ending, even when legal action is left. The US Food and Drug Administration is now preventing the sale of the cheap compound version of the drug that Vigo and Zipbound and its related diabetes medicines – Ozampic and Moonagaro – are no longer lacking.

Morning Star Healthcare analyst Karen Anderson said selling cheap verses of drugs has been a huge lucrative driver for these companies, and the loss is a problem.

Anderson said that a way forward for welfare companies is to work with brand name drugs.

“Companies like Novo need, they need partners who have access to patients,” he said. But finding the creative ways of partnership with major competitors is not a small task, he added. “This will be a rocky way.”